Executive Summary
Artificial intelligence is moving rapidly into some of the most regulated areas of the life sciences industry.
Pharmaceutical companies are using AI to analyze scientific data, support clinical development, monitor manufacturing processes, manage quality systems, and improve regulatory workflows. Yet deploying AI in a regulated environment creates a fundamental challenge: how can organizations demonstrate that an AI system is reliable, controlled, and appropriate for its intended use?
Traditional software validation provides an important foundation, but AI introduces additional considerations.
AI systems can produce probabilistic outputs, change as models or data evolve, and behave differently across datasets and scenarios. Generative AI adds further complexity because outputs may vary between interactions.
AI validation therefore needs to move beyond simply testing whether software performs a predefined function.
It must also address data quality, model performance, intended use, explainability, change management, human oversight, and ongoing monitoring.
For pharmaceutical companies, effective AI validation will become essential to scaling AI responsibly while maintaining product quality, patient safety, data integrity, and regulatory compliance.
Why Is AI Validation Different From Traditional Software Validation?
Traditional software generally follows predefined rules.
If the same inputs and conditions are provided, the system is expected to produce a predictable result. Validation can therefore focus heavily on confirming that the software consistently performs its specified functions.
AI systems can behave differently.
Machine learning models identify patterns from data and generate predictions based on those patterns. Their performance can vary depending on the data presented to them.
Generative AI introduces even greater variability.
This means validation needs to evaluate not only whether the technology functions correctly, but also whether its outputs are sufficiently accurate, reliable, and appropriate for the intended application.
What Does AI Validation Need to Demonstrate?
The first requirement is a clearly defined intended use.
A pharmaceutical company needs to establish what the AI system is designed to do, who will use it, what decisions it may support, and what risks could arise from incorrect outputs.
Validation can then be built around that specific use case.
Important considerations include:
- Accuracy and performance
- Data quality and representativeness
- Model robustness
- Reproducibility
- Security and access controls
- Auditability
- Human oversight
- Change management
The level of validation should correspond to the potential impact of the AI system.
An AI tool used to summarize internal information does not necessarily present the same risk as a model supporting a manufacturing quality decision.
How Important Is Data Quality?
AI validation begins with the data.
A sophisticated model cannot compensate for inaccurate, incomplete, biased, or poorly governed data.
Pharmaceutical companies therefore need to understand where training and operational data originate, how they are processed, and whether they are representative of the intended use.
Data lineage is particularly important.
Organizations should be able to establish which datasets influenced a model and whether important changes to those datasets could affect performance.
For regulated applications, data governance and AI validation are therefore closely connected.
How Should AI Models Be Tested?
AI models need to be evaluated against appropriately designed test datasets.
Testing should examine more than average performance.
Organizations should consider how the model behaves with unusual inputs, incomplete information, different patient or product populations, and other scenarios relevant to the intended application.
Performance thresholds should be established before deployment where possible.
The testing process should also document limitations.
A model that performs well under normal conditions but fails in specific scenarios may still be unsuitable for a particular regulated use.
Understanding those boundaries is an important part of validation.
Can AI Models Be Validated Once and Left Alone?
Generally, AI validation cannot be treated as a one-time event.
Traditional software may remain relatively stable after deployment. AI systems can change when models are retrained, datasets are updated, algorithms are modified, or external AI services change.
Even without deliberate modifications, performance can change if the data environment changes.
This makes ongoing monitoring important.
Companies should establish processes for detecting performance degradation, investigating unexpected behavior, and determining when revalidation is required.
The validation lifecycle therefore needs to extend beyond initial deployment.
What About Generative AI?
Generative AI presents additional validation challenges.
Large language models can produce different outputs for similar inputs and may generate information that sounds convincing but is incorrect.
For regulated applications, organizations need controls around the sources of information, output review, prompt design, model configuration, and human approval.
Use cases should also be clearly categorized according to risk.
Generative AI used to help employees locate approved information presents a different risk profile from a system generating content that could directly influence a regulated submission or product-quality decision.
The validation approach should reflect this difference.
How Does Human Oversight Fit Into AI Validation?
Human oversight remains an important control.
In many regulated applications, AI should support rather than replace qualified professionals.
The validation process should therefore evaluate not only the model but also the human-AI workflow.
Employees need to understand when AI outputs require verification, what types of errors can occur, and when decisions must be escalated.
This is particularly important because users may place excessive confidence in systems that appear highly capable.
A well-designed validation framework should make human accountability explicit.
How Does AI Validation Apply to Manufacturing?
Pharmaceutical manufacturing is one of the most important areas for regulated AI.
AI may be used to monitor processes, predict equipment failures, detect anomalies, or identify potential quality risks.
Because these applications can affect product quality, validation needs to demonstrate that the system performs reliably under relevant manufacturing conditions.
Organizations should establish appropriate acceptance criteria and evaluate how the system responds to changing process conditions.
Any AI system influencing GMP-related activities should also be integrated into established quality and change-control processes.
What About Clinical and Patient-Related Applications?
AI used in clinical development can support areas such as patient recruitment, trial monitoring, data analysis, and medical information processing.
Validation becomes particularly important when AI outputs could influence decisions involving patients or clinical evidence.
Sponsors need to understand the model’s intended population, data limitations, performance characteristics, and potential sources of bias.
Where AI supports high-impact decisions, human review and appropriate documentation become especially important.
The closer an AI application gets to patient safety or clinical decision-making, the stronger the validation expectations are likely to be.
How Should Companies Manage AI Changes?
AI systems evolve quickly.
A model update, new training dataset, prompt change, software upgrade, or change in an underlying foundation model could affect performance.
Pharmaceutical companies therefore need AI-specific change-control processes.
Organizations should define which changes require assessment, testing, or full revalidation.
For third-party AI services, this becomes particularly important because the company may not control every aspect of the underlying technology.
Vendor management should therefore include appropriate information about model updates, performance changes, security, and service dependencies.
What Role Will Regulators Play?
Regulatory expectations around AI continue to evolve as the technology becomes more widely used.
Regulators will need assurance that AI systems used in regulated processes are appropriately controlled and that companies understand their limitations.
Pharmaceutical organizations should therefore avoid treating regulatory compliance as something addressed only after an AI system has been deployed.
Early engagement with relevant regulatory functions can help determine appropriate validation strategies for higher-risk applications.
The ability to explain how an AI system was developed, tested, monitored, and governed will become increasingly important.
What Should Pharma Leaders Do Now?
Companies should establish an enterprise AI validation framework rather than creating separate approaches for every individual project.
The framework should connect AI governance with existing quality, computer system validation, data governance, cybersecurity, and risk-management processes.
Leaders should also classify AI applications according to risk and apply proportional controls.
Lower-risk productivity applications can support faster experimentation, while systems affecting product quality, patient safety, or regulated evidence require substantially stronger validation.
This approach can prevent both under-control and unnecessary bureaucracy.
What Will the Future of AI Validation Look Like?
AI validation will likely become a continuous discipline.
Automated monitoring could track model performance, data changes, unexpected outputs, and other indicators after deployment.
Validation processes may also become increasingly integrated into AI development pipelines, allowing organizations to test models continuously rather than waiting for major releases.
This could create a lifecycle in which AI systems are evaluated from development through deployment and ongoing operation.
As AI becomes embedded throughout pharmaceutical organizations, validation will increasingly become part of the technology architecture rather than a final compliance checkpoint.
Conclusion
AI validation is becoming a critical capability for pharmaceutical companies operating in regulated environments.
The challenge is not simply proving that an AI application works. Organizations must demonstrate that it is appropriate for its intended use, supported by reliable data, appropriately tested, monitored over time, and governed according to its risk.
This requires a broader approach than traditional software validation.
Companies will need to combine model evaluation, data governance, human oversight, change control, cybersecurity, and continuous monitoring.
The objective should not be to slow AI adoption.
It should be to create the confidence required to scale it.
As AI becomes increasingly embedded in clinical research, manufacturing, quality, and regulatory operations, organizations that build strong validation capabilities will be better positioned to capture its benefits while protecting the standards on which pharmaceutical development depends.
AI Validation is becoming increasingly important as pharmaceutical, biotechnology, medical device, and healthcare organizations adopt artificial intelligence in regulated processes. AI systems can influence manufacturing, quality management, clinical development, regulatory submissions, and other activities where accuracy and traceability are essential.
The FDA’s current approach emphasizes risk-based assurance for computerized systems and appropriate validation evidence. Its 2026 Computer Software Assurance guidance describes a risk-based approach for establishing confidence in automation used in production and quality management systems.
Why AI Validation Matters
AI Validation helps organizations demonstrate that an AI system performs consistently for its intended purpose. Unlike traditional software, AI models can introduce additional challenges involving training data, model behavior, performance changes, and ongoing monitoring.
